Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

749 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Fosså S, Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, de Reijke TM, Robson CN, De Santis M, Seruga B, de Wit R. Fitzpatrick JM, et al. Among authors: di lorenzo g. Eur J Cancer. 2014 Jun;50(9):1617-27. doi: 10.1016/j.ejca.2014.03.010. Epub 2014 Apr 3. Eur J Cancer. 2014. PMID: 24703899 Free article.
Targeted therapy in the treatment of metastatic renal cell cancer.
Di Lorenzo G, Scagliarini S, Di Napoli M, Scognamiglio F, Rizzo M, Carteni' G. Di Lorenzo G, et al. Among authors: di napoli m. Oncology. 2009;77 Suppl 1:122-31. doi: 10.1159/000258504. Epub 2010 Feb 2. Oncology. 2009. PMID: 20130440 Review.
Toxicities of targeted therapy and their management in kidney cancer.
Di Lorenzo G, Porta C, Bellmunt J, Sternberg C, Kirkali Z, Staehler M, Joniau S, Montorsi F, Buonerba C. Di Lorenzo G, et al. Eur Urol. 2011 Apr;59(4):526-40. doi: 10.1016/j.eururo.2011.01.002. Epub 2011 Jan 14. Eur Urol. 2011. PMID: 21277078 Review.
Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.
Buonerba C, Federico P, D'Aniello C, Rescigno P, Cavaliere C, Puglia L, Ferro M, Altieri V, Perdonà S, De Placido S, Di Lorenzo G. Buonerba C, et al. Among authors: di lorenzo g. Cancer Chemother Pharmacol. 2011 Jun;67(6):1455-61. doi: 10.1007/s00280-011-1594-z. Epub 2011 Mar 2. Cancer Chemother Pharmacol. 2011. PMID: 21365219 Clinical Trial.
Immunotherapy for the treatment of prostate cancer.
Di Lorenzo G, Buonerba C, Kantoff PW. Di Lorenzo G, et al. Nat Rev Clin Oncol. 2011 May 24;8(9):551-61. doi: 10.1038/nrclinonc.2011.72. Nat Rev Clin Oncol. 2011. PMID: 21606971 Review.
749 results